U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H54N8
Molecular Weight 502.782
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLERIXAFOR

SMILES

C(N1CCCNCCNCCCNCC1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2

InChI

InChIKey=YIQPUIGJQJDJOS-UHFFFAOYSA-N
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2

HIDE SMILES / InChI

Description

Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
44.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MOZOBIL
Primary
MOZOBIL

Cmax

ValueDoseCo-administeredAnalytePopulation
1029 ng/mL
240 μg/kg bw single, subcutaneous
PLERIXAFOR plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
5260 ng × h/mL
240 μg/kg bw single, subcutaneous
PLERIXAFOR plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.6 h
240 μg/kg bw single, subcutaneous
PLERIXAFOR plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Begin treatment with plerixafor (Mozobil) after the patient has received G-CSF once daily for four days. The recommended dose of plerixafor by subcutaneous injection is based on body weight: 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg; 0.24 mg/kg of body weight for patients weighing >83 kg. Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis.
Route of Administration: Other
In Vitro Use Guide
Human colorectal cancer cell line SW480 was treated with plerixafor at different final concentrations (10, 100, 1000 ng/ml) for 2h. Then, CXCL12 was added daily at 20 ng/mL. MTT assays were performed after 24, 48 and 72 h of plerixafor treatment. Cell viability was significantly suppressed by the drug in a dose-dependent manner. The drug (100 and 1000 ng/mL) significantly inhibited the invasion ability of SW480 cells.